Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
Los Angeles Times - Monday, July 8 2002
Thomas H. Maugh II, Times Staff Writer
The drug, called T-20, is the first member of a long-awaited family of drugs called fusion inhibitors that block the entry of HIV into cells. The four existing classes of drugs block enzymes that enable the virus to replicate, so T-20 represents an alternative approach to halting viral spread within the body.
Researchers will report on two major trials of more than 1,000 patients who were not responding well to treatment with other AIDS drugs. T-20 reduced blood virus levels by nearly three-quarters and doubled the percentage of patients in which the virus fell to undetectable levels, the teams will tell the 14th International AIDS Conference.
The results are considered quite powerful because the study was conducted "among heavily treatment-experienced patients, a population for whom treatment options are limited," Dr. Jay Lalezari of Quest Clinical Research in San Francisco, who headed one of the studies, said in an interview here. The findings are "exciting and encouraging," he added.
The drug is a "major step forward" in HIV treatment, added Dr. Carl Dieffenbach of the National Institute of Allergy and Infectious Diseases.
T-20 was developed by Trimeris Inc. and will be marketed by Hoffmann-La Roche Inc. Based on the test results, the companies hope to obtain Food and Drug Administration approval for it by the end of the year.
There are 16 drugs in the four classes approved for treating HIV infection. Three of the classes are different families of drugs that block a crucial viral enzyme called reverse transcriptase. Members of the fourth family block a second enzyme, called protease. Both enzymes are crucial to viral replication within cells.
T-20, in contrast, prevents the virus from entering cells, which it does by fusing with the membrane of a target cell, a crucial step in infection. That fusion is carried out by a viral protein called gp 41.
The new drug is a small protein that blends with gp 41, thereby preventing it from fusing with the cellular membrane. Because it is a protein, however, T-20 cannot be given orally. Instead, it is administered twice daily by injections.
But also because it is a protein, the drug does not interfere with cellular metabolic processes or interact with other AIDS medications, said Dr. Dani Bolognesi, CEO of Trimeris. So there are very few side effects, he said.
In fact, the most common adverse effect has been a rash or other mild reaction at the injection site. Only 3% of subjects chose to discontinue drug use because of side effects.
The subjects in the two studies had all been treated with an average of 11 or 12 other AIDS drugs before entering the trials. For each patient, physicians devised a regimen of three new AIDS drugs that appeared to offer the best hope of reducing HIV. Half of these patients received T-20 as well.
After 24 weeks, 37% of the patients who received T-20 in one study had undetectable blood levels of HIV, compared with 16% of those who received just the three-drug cocktail. In the second study, the corresponding figures were 28% and 14%. Patients in earlier studies have sustained such reductions for 96 weeks or longer, said Dr. James A. Thommes, medical director of Roche.
020708
LT020705
Copyright © 2002 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .